Fasting Insulin and Medication-Driven Changes: What Every Woman Needs to Know

Why Fasting Insulin Matters More for Women Than Standard Glucose Tests

A normal fasting glucose and a normal HbA1c can coexist with dramatically elevated fasting insulin. That is the core problem. When your cells resist insulin's signal, your pancreas compensates by secreting more of it. Blood sugar stays normal for years while the underlying dysfunction worsens. Fasting insulin catches this compensatory hyperinsulinemia long before glucose rises.

For women specifically, this matters because insulin resistance is woven into several female-dominant conditions: polycystic ovary syndrome (PCOS), endometriosis, hormonal acne, female-pattern weight gain, and the metabolic shift of the menopausal transition. A 2019 analysis in Fertility and Sterility found that 70 to 80% of women with PCOS have measurable insulin resistance, regardless of BMI. Standard metabolic panels miss most of them.

Medications you may be taking right now, for reasons entirely unrelated to blood sugar, can push your fasting insulin up or down by 20 to 50%. Understanding which drugs do what, and by how much, is essential for interpreting your own lab result correctly.

What Is the Optimal Fasting Insulin Range for Women?

Most commercial labs flag fasting insulin as abnormal only above 24 or 25 µIU/mL. That cutoff reflects statistical norms from population samples that historically included few women with PCOS and rarely stratified by hormonal status. It is a low bar.

Functional vs. Laboratory Reference Ranges

Functional and longevity medicine practitioners generally use a tighter optimal target: 2 to 6 µIU/mL fasting. Values between 6 and 10 µIU/mL suggest early compensatory hyperinsulinemia. Values above 10 µIU/mL fasting are consistent with meaningful insulin resistance in most women, even when glucose remains normal.

The American Association of Clinical Endocrinology (AACE) does not specify a single fasting insulin cutoff but endorses insulin resistance assessment in women with PCOS, obesity, or prediabetes. In practice, the 2 to 6 µIU/mL target is the one most reproductive endocrinologists use when optimizing fertility or PCOS management.

How Lab Collection Affects the Number

Fasting insulin is highly sensitive to collection conditions. A 12-hour fast is standard. Anything less than 8 hours can artificially raise the result by 15 to 30%. Acute physical or emotional stress raises cortisol, which raises glucose, which provokes an insulin response. Collect your blood when you are genuinely fasted and calm, ideally on a rest day.

Medications That Lower Fasting Insulin

Metformin

Metformin is the most studied insulin-sensitizing drug in women. In PCOS, multiple randomized trials show it reduces fasting insulin by 20 to 30% over 3 to 6 months. The ESHRE/ASRM-sponsored consensus (2018) names metformin as a first-line medical therapy for metabolic features of PCOS across reproductive years and into perimenopause. It works primarily by reducing hepatic glucose output, which lowers the insulin signal needed to maintain euglycemia.

One nuance: metformin does not lower fasting insulin to the same degree in all women. Lean women with PCOS and normal fasting glucose tend to see smaller absolute drops than women with concurrent obesity. Response typically plateaus at doses of 1,500 to 2,000 mg/day.

GLP-1 Receptor Agonists

GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro, Zepbound), lower fasting insulin through two mechanisms: they reduce food intake (less postprandial glucose load) and they improve peripheral insulin sensitivity. The STEP 1 trial reported that semaglutide 2.4 mg weekly reduced fasting insulin by approximately 30 to 35% at 68 weeks in adults with obesity, a population that was majority female. Tirzepatide data from SURMOUNT-1 showed similar or slightly larger reductions.

Women with PCOS are an important subgroup here. Small RCTs suggest GLP-1 agonists reduce fasting insulin by 25 to 40% in this population specifically, with concurrent improvements in androgen levels, which makes clinical sense: hyperinsulinemia directly stimulates ovarian androgen production.

Inositol Supplements

Myo-inositol and D-chiro-inositol are not prescription drugs, but they are widely used by women with PCOS and are worth naming here because many women take them alongside or instead of metformin. A 2019 Cochrane-adjacent systematic review published in BJOG found that myo-inositol (4 g/day) reduced fasting insulin by a mean of 4.1 µIU/mL compared with placebo in women with PCOS. That is a clinically meaningful shift if your baseline is 12 to 15 µIU/mL.

SGLT-2 Inhibitors

Empagliflozin, dapagliflozin, and canagliflozin lower blood glucose by promoting urinary glucose excretion. Lower glucose means lower insulin stimulus. In women with type 2 diabetes, fasting insulin can drop 15 to 25% after 12 weeks of SGLT-2 inhibition. These drugs are increasingly used off-label in prediabetes and are being studied in PCOS, though trial data in women with PCOS specifically remains limited. That evidence gap should be stated plainly: what we know about SGLT-2 inhibitors in non-diabetic women with hyperinsulinemia is mostly extrapolated from diabetic or mixed-sex populations.

Thiazolidinediones (TZDs)

Pioglitazone and rosiglitazone are PPAR-gamma agonists that improve insulin sensitivity at the muscle and fat level. In women with PCOS, pioglitazone 30 mg/day reduced fasting insulin by roughly 25% in a 6-month RCT and improved ovulation rates. TZDs are rarely used as first-line today because of weight gain and bone loss concerns, the latter particularly relevant for women at risk for osteoporosis. If you are perimenopausal and already managing bone density, TZDs deserve a careful conversation with your clinician.

Medications That Raise Fasting Insulin

Corticosteroids

Oral, inhaled high-dose, and injectable corticosteroids (prednisone, dexamethasone, methylprednisolone) cause steroid-induced hyperglycemia through two pathways: they increase hepatic glucose output and they impair peripheral insulin uptake. The pancreas compensates with higher insulin secretion. Fasting insulin can rise measurably within 48 to 72 hours of starting a course of oral prednisone, and in women already at the margins of insulin resistance, this can tip them into a prediabetic pattern. The effect resolves as the steroid is tapered, but women with PCOS or prior gestational diabetes should be monitored more closely during and after steroid courses.

Antipsychotics

Second-generation antipsychotics (olanzapine, clozapine, quetiapine) are strongly associated with insulin resistance and weight gain. A meta-analysis in JAMA Psychiatry found that olanzapine raised fasting insulin by a mean of 3.4 µIU/mL compared with placebo after just 8 weeks, even before meaningful weight change occurred. Women on these drugs for bipolar disorder or schizophrenia should have fasting insulin checked at baseline, at 3 months, and annually, a recommendation not always followed in routine psychiatric care.

Certain Hormonal Contraceptives

This is a nuanced area. Combined oral contraceptives (COCs) with older, androgenic progestins (levonorgestrel, norethindrone) can modestly raise fasting insulin and worsen insulin sensitivity. A 2023 analysis in Contraception found that levonorgestrel-containing pills raised HOMA-IR (a calculated insulin resistance index) by about 12% compared with baseline in women with PCOS. Newer progestins with anti-androgenic profiles (drospirenone, dienogest) appear to have a more neutral or even slightly beneficial effect on insulin sensitivity.

The progestin-only pill (POP) and hormonal IUDs (levonorgestrel-releasing) have very low systemic absorption and generally do not produce clinically meaningful changes in fasting insulin in most women. If your fasting insulin rises after starting a COC and you have underlying PCOS or insulin resistance, ask your clinician whether a different formulation or method makes more sense.

Beta-Blockers

Non-selective beta-blockers (propranolol, atenolol) impair insulin secretion and may simultaneously raise baseline insulin levels through complex counter-regulatory mechanisms. The effect is most pronounced with non-selective agents compared with cardioselective ones. Women on beta-blockers for migraine prophylaxis or anxiety, a common off-label use, often do not have their metabolic effects discussed at all.

How Life Stage Changes Your Fasting Insulin Interpretation

Reproductive Years and PCOS

During your reproductive years, PCOS is the dominant driver of elevated fasting insulin. If your fasting insulin is above 10 µIU/mL and you have irregular cycles, acne, or excess hair growth, PCOS-related insulin resistance is high on the differential. The 2023 international PCOS guideline from ASRM and partners explicitly recommends metabolic assessment, including insulin resistance markers, in all women with PCOS regardless of BMI.

Trying to Conceive and Fertility Treatment

Elevated fasting insulin impairs ovulation and implantation. In women undergoing IVF, a pre-treatment fasting insulin above approximately 10 µIU/mL has been associated with lower live birth rates in observational data. Reducing fasting insulin with metformin before and during IVF is supported by a 2022 Cochrane review showing improved clinical pregnancy rates in women with PCOS using metformin alongside gonadotropins.

Pregnancy

Fasting insulin is not a standard prenatal test. Gestational diabetes is diagnosed by the 1-hour 50-gram glucose challenge test followed by the 3-hour 100-gram oral glucose tolerance test (OGTT), per ACOG Practice Bulletin 190. Fasting insulin has no formal role in that diagnostic pathway. Some integrative providers measure it at the first prenatal visit in women with PCOS or prior insulin resistance, but this is not standard practice and the data to guide clinical decisions based on first-trimester fasting insulin is limited.

Women who are pregnant should not start or continue insulin-sensitizing drugs (metformin excepted under specific circumstances, pioglitazone and SGLT-2 inhibitors contraindicated) without explicit OB guidance.

Perimenopause and Post-Menopause

This is the life stage most overlooked in the fasting insulin literature. Estrogen promotes insulin sensitivity in skeletal muscle. As estrogen declines during perimenopause, insulin resistance rises even in women who maintain their weight and exercise habits. A 2021 study in Menopause found that insulin sensitivity decreased by approximately 15% across the menopausal transition independent of fat mass changes. This means a fasting insulin that was 5 µIU/mL at age 42 might be 8 to 10 µIU/mL at age 52 without any change in diet or medication.

Menopausal hormone therapy (MHT) with transdermal estradiol appears to partially restore insulin sensitivity. Oral estrogen is more metabolically mixed because of first-pass hepatic effects. The Menopause Society 2022 position statement notes that transdermal estradiol has a more favorable effect on insulin sensitivity than oral formulations, though it does not establish a specific fasting insulin target for MHT initiation.

Pregnancy and Lactation: What You Need to Know

Fasting insulin testing itself carries no risk in pregnancy. The clinical question is what to do about abnormal results and whether drugs that affect fasting insulin are safe to continue.

Metformin in Pregnancy

Metformin is FDA Pregnancy Category B (pre-2015 categorization) with a generally reassuring safety profile through the first trimester in women with PCOS or type 2 diabetes. The MiG (Metformin in Gestational Diabetes) trial found comparable neonatal outcomes between metformin and insulin in gestational diabetes, with higher patient satisfaction in the metformin group. Metformin crosses the placenta; long-term offspring data beyond age 9 is still accumulating and is not yet fully reassuring. ACOG states metformin is an acceptable alternative to insulin for gestational diabetes in women who prefer oral therapy, but the decision requires informed consent about the existing uncertainty.

Metformin transfers into breast milk in small amounts. The relative infant dose is generally below 1%, which most lactation specialists consider acceptable. The LactMed database lists metformin as compatible with breastfeeding.

GLP-1 Agonists in Pregnancy

GLP-1 receptor agonists are contraindicated in pregnancy. Animal data show fetal harm at high doses, and human safety data is absent. The FDA label for semaglutide explicitly states: discontinue at least 2 months before a planned pregnancy. If you are taking a GLP-1 agonist and become pregnant, stop the drug and contact your OB immediately. Because GLP-1 agonists cause weight loss, which can restore ovulation in anovulatory women with PCOS, unintended pregnancy is a real risk. Use reliable contraception while on these drugs.

SGLT-2 Inhibitors and TZDs in Pregnancy

Both drug classes are contraindicated in pregnancy. SGLT-2 inhibitors carry an FDA warning for fetal renal toxicity in the second and third trimesters. Pioglitazone has animal teratogenicity data and should be stopped before conception.

Corticosteroids in Pregnancy

Short courses of corticosteroids are sometimes necessary in pregnancy (for fetal lung maturation, autoimmune flares). They raise maternal glucose and insulin transiently. Women with pre-existing insulin resistance need additional glucose monitoring during steroid courses in pregnancy.

Who This Is Right For and Who Should Think Twice

Women Who Benefit Most From Fasting Insulin Testing

• Women with PCOS at any age, regardless of BMI
• Women with irregular cycles and difficulty conceiving
• Women in perimenopause with new weight gain concentrated around the abdomen
• Women with a personal or family history of type 2 diabetes or gestational diabetes
• Women starting or stopping medications known to affect insulin sensitivity (corticosteroids, antipsychotics, hormonal contraceptives)
• Women on GLP-1 agonists or metformin who want objective evidence of therapeutic response

Women Who Should Interpret Results Cautiously

• Women currently on corticosteroids: results reflect drug effect, not baseline physiology
• Women who fasted fewer than 8 hours or who were acutely stressed at the time of collection
• Women post-partum and breastfeeding: hormonal flux and sleep disruption both affect insulin sensitivity in ways that make a single fasting insulin harder to interpret
• Women with type 1 diabetes: endogenous insulin production is impaired; fasting insulin is not a useful marker of insulin resistance in this setting

Understanding HOMA-IR: The Calculation That Gives Fasting Insulin Context

Fasting insulin alone is more useful when paired with a simultaneous fasting glucose to calculate HOMA-IR (Homeostatic Model Assessment of Insulin Resistance). The formula:

HOMA-IR = (Fasting insulin [µIU/mL] × Fasting glucose [mmol/L]) / 22.5

A HOMA-IR below 1.0 is optimal. Above 2.0 suggests insulin resistance. Above 2.9 is the threshold used in many PCOS studies to define significant insulin resistance, including the landmark Rotterdam criteria follow-up analyses. Because HOMA-IR incorporates both variables, it is less susceptible to a single outlier fasting insulin measurement driven by stress or incomplete fasting.

One honest caveat: HOMA-IR was derived and validated in populations that did not include large numbers of women with PCOS or women in menopause. The 2.9 cutoff may misclassify some women. This is an evidence gap that has not been fully closed. Several researchers argue that a cutoff of 2.0 is more appropriate for women in reproductive years, based on sensitivity analyses from PCOS-specific datasets.

Practical Steps After Getting Your Fasting Insulin Result

If your fasting insulin is above 6 µIU/mL and you are not already on a drug that raises it artificially, this is a signal worth acting on, not watching passively.

First, check your collection conditions. Were you genuinely fasted for 12 hours? Were you well-rested? Repeat the test under controlled conditions before making medication changes.

Second, calculate your HOMA-IR using the simultaneous fasting glucose from the same blood draw. Most labs include fasting glucose on a basic metabolic panel run at the same visit.

Third, ask your clinician whether a medication you are already taking is driving the result. Bring a complete medication list including over-the-counter supplements. Corticosteroid courses, even recent ones that have finished, can leave a metabolic footprint for weeks.

Fourth, if PCOS has not been formally assessed and your fasting insulin is above 10 µIU/mL with any irregular cycle history, ask for a full PCOS workup: testosterone (total and free), DHEA-S, LH/FSH ratio, and a pelvic ultrasound.

Fifth, if you are in perimenopause and your fasting insulin has risen over successive years without major lifestyle changes, a conversation about transdermal estrogen as part of MHT is warranted, particularly if you have other indications for it. A 2021 EMAS (European Menopause and Andropause Society) statement confirmed that transdermal estradiol lowers insulin resistance markers in postmenopausal women without the clot risk of oral formulations.

Women with a fasting insulin above 15 µIU/mL combined with a HOMA-IR above 2.9, irregular cycles, and other features of metabolic dysfunction should not wait for a formal type 2 diabetes diagnosis before starting treatment. The 2023 AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm supports metformin initiation in high-risk prediabetes states, which this clinical picture represents.